



AstraZeneca Closes Acquisition of Amolyt Pharma

Lyon, France, and Cambridge, MA, July 15, 2024 — Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced that its previously [announced](#) acquisition by the global pharmaceutical company, AstraZeneca, has closed.

The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism. In patients with hypoparathyroidism, a deficiency in parathyroid hormone (PTH) production results in significant dysregulation of calcium and phosphate, which can lead to life-altering symptoms and complications, including chronic kidney disease. This programme, together with Amolyt's talented team, expertise, and earlier pipeline, will enable Alexion's expansion into rare endocrinology.

Under the terms of the definitive agreement, AstraZeneca has acquired all of Amolyt Pharma's outstanding shares for a total consideration of up to \$1.05 billion, on a cash and debt free basis. This includes \$800 million upfront at deal closing, plus the right for Amolyt Pharma's shareholders to receive an additional contingent payment of \$250 million payable upon achievement of a specified regulatory milestone.

About Amolyt Pharma

Amolyt Pharma, a clinical stage biotechnology company, is building on its team's established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. To learn more, visit <https://amolytpharma.com/> or follow us on Twitter and LinkedIn.

Amolyt Contact:

Patrick Loustau

Chief Business Officer

ploustau@amolyt.com

Media inquiries:

Jordyn Temperato

LifeSci Communications

jtemperato@lifescicomms.com